| abstract |
(57) [Summary] Formula (I): Wherein R 0 is CR 4 R 5 —X 1 —Y 1 , CR 4 R 5 —X 2 —Y 2 or (CH 2 ) pX 3 (CH 2 ) qY 3 ; R 1 and R 2 may be the same or different and are each selected from hydrogen, halogen or C (1-8) alkyl; R 4 and R 5 may be the same or different and each represent hydrogen and C (1- 6) selected from alkyl, or R 4 and R 5 may be linked together to form a residue of a C (3-7) cycloalkyl ring; X 1 is a linking group; Y 1 is an optionally substituted C (1-12) alkyl C (2-12) alkenyl, C (2-12) alkynyl, C (3-7) cycloalkylC (1-8) alkyl by and; X 2 is a linking group, Y 2 is optionally be heteroaryl group which may be substituted; X 3 is a heteroaryl group, Y 3 is optionally substituted An aryl group which may have, p is an integer from 1 to 6, q is 0 or an integer from 1 to 6; Z is O, R 3 is C (1-8) alkyl , Aryl C (1-4) alkyl or aryl, each of which is optionally substituted, or Z is S (O) n, wherein n is 0, 1 or R 3 is C (1-8) alkyl, C (3-8) cycloalkyl, C (3-8) cycloalkyl C (1-6) alkyl, aryl, aryl C (1 -4) alkyl or heteroaryl C (1-4) alkyl (wherein each of the compound represented by optionally is optionally substituted)], be inhibitors of phospholipase A2 enzyme Lp-PLA 2 , For example, in the treatment of atherosclerosis. |